FKBP Ligands: Novel Strategies for the
Treatment of Neurodegenerative Disorders


Edited by

Bruce G. Gold, Ph.D.
Center for Research on Occupational and Environmental Toxicology, Oregon Health Sciences University, Portland, Oregon, USA

Gunter Fischer, Ph.D.
Max-Planck-Research Unit, Enzymology of Protein Folding, Halle, Germany

Thomas Herdegen, Ph.D.
Institute of Pharmacology, University of Kiel, Kiel, Germany

The neuroimmunophilin field began with three independent discoveries reported between 1992 and 1994: first, that immunophilins, the binding proteins for immunosuppressant drugs such as cyclosporin A, FK-506 and rapamycin, exist in the brain (neuroimmunophilins); second, that FK-506 reduces infarction following focal cerebral ischemia; and third, that FK-506 accelerates nerve regeneration in the sciatic nerve crush model. These seminal discoveries sparked great interest in neuroimmunophilins as potential targets for therapeutic intervention for a variety of neurological conditions including peripheral nerve and spinal cord injuries, ischemic damage and Parkinson’s disease.

This book is the result of the proceedings of the first conference on neuroimmunophilins held July 9-11, 1999, and explores the function of immunophilin-FKBP-ligands in neurodegenerative diseases and their clinical use with contributions from researchers from a variety of disciplines working in both academic and pharmaceutical settings. The conference and the book represent a long overdue milestone and will be the impetus for others to enter this exciting new field.

Fall 2000
84-8124-165-2
xviii + 286 pages
Softcover, 15.5 x 23.5 cm
US $85.00